605655-08-1

Basic information

• Product Name: 1-BOC-3-(TOLUENE-4-SULFONYLOXY)-AZETIDINE
• Synonyms: 1-BOC-3-(TOLUENE-4-SULFONYLOXY)-AZETIDINE;tert-Butyl 3-(tosyloxy)azetidine-1-carboxylate;1-BOC-3-Tosyloxyazetidine
• CAS NO: 605655-08-1
• Molecular Formula: C₁₅H₂₁NO₅S
• Molecular Weight: 327.4
• Mol File: 605655-08-1.mol

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 1-BOC-3-(TOLUENE-4-SULFONYLOXY)-AZETIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: 1-BOC-3-(TOLUENE-4-SULFONYLOXY)-AZETIDINE(605655-08-1)
• EPA Substance Registry System: 1-BOC-3-(TOLUENE-4-SULFONYLOXY)-AZETIDINE(605655-08-1)

Safety Data

• Hazardous Substances Data: 605655-08-1(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Research:
1-BOC-3-(TOLUENE-4-SULFONYLOXY)-AZETIDINE is used as a building block for the synthesis of various pharmaceutical compounds. Its unique chemical properties allow for the creation of diverse chemical structures, contributing to the development of new drugs and therapeutic agents.
Used in Organic Synthesis:
In the field of organic synthesis, 1-BOC-3-(TOLUENE-4-SULFONYLOXY)-AZETIDINE is used as a versatile intermediate. Its BOC protecting group and toluene-4-sulfonyloxy leaving group enable a wide range of nucleophilic substitution reactions, facilitating the synthesis of complex organic molecules and expanding the scope of chemical research.
Used in Chemical Structure Preparation:
1-BOC-3-(TOLUENE-4-SULFONYLOXY)-AZETIDINE is employed as a key intermediate in the preparation of diverse chemical structures. Its unique properties make it an essential component in the synthesis of complex organic compounds, furthering the understanding of chemical reactions and the development of novel chemical entities.

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 398489-26-4 tert-butyl 3-oxoazetidine-1-carboxylate 
• 98-59-9 p-toluenesulfonyl chloride 
• 141699-55-0 tert-butyl 3-hydroxyazetidine-1-carboxylate 

Downstream Products

• 1332301-51-5 tert-butyl 3-(2,4-dichlorophenoxy)azetidine-1-carboxylate 
• 960492-52-8 tert-butyl 3-(2-(trifluoromethyl)phenoxy)-azetidine-1-carboxylate 
• 1310732-18-3 tert-butyl 3-(chlorosulfonyl)azetidine-1-carboxylate 
• 1462379-19-6 tert-butyl 3-(4-fluorophenoxy)azetidine-1-carboxylate 
• 1314987-79-5 tert-butyl 3-(4-nitro-1H-pyrazol-1-yl)azetidine-1-carboxylate 
• 1582272-26-1 (E)-tert-butyl ((1-benzyl-5-(3-ethylpent-3-en-2-yl)-1H-pyrrol-3-yl)methyl)carbamate 
• 1582272-27-2 (Z)-tert-butyl ((1-benzyl-5-(3-ethylpent-3-en-2-yl)-1H-pyrrol-3-yl)methyl)carbamate 
• 1582272-24-9 tert-butyl ((1-(2-chlorobenzyl)-4-(1,3-dioxoisoindolin-2-yl)-5-phenyl-1H-pyrrol-3-yl)methyl)carbamate 
• 1582272-01-2 tert-butyl 3-(1-(1,3-dioxoisoindolin-2-yl)-2-oxo-2-phenylethyl)-2-((ethoxycarbon-othioyl)thio)azetidine-1-carboxylate 
• 1582272-23-8 ethyl 4-(((tert-butoxycarbonyl)amino)methyl)-1-(2-chlorobenzyl)-2-methyl-1H-pyrrole-3-carboxylate 

Relevant articles and documents

COMPOUNDS AND USES THEREOF

The present disclosure features compounds and methods useful for the treatment of BAF complex-related disorders.

COMPOUND SERVING AS IRAK INHIBITOR

The present disclosure relates a compound as an IRAK inhibitor. Specifically, the present disclosure provides a compound of formula I, or a cis-trans isomer, an optical isomer, a racemate, a pharmaceutically acceptable salt, a prodrug, a deuterated derivative thereof, a hydrate or a solvate thereof. The compounds disclosed herein have potent inhibitory effects on IRAK and thus have therapeutic effect on IRAK-related diseases.

PENTAFLUOROBENZENESULFONAMIDE DERIVATIVES AND USES THEREOF

Provided herein are pentafluorobenzenesulfonamide compounds of Formula (I), pharmaceutical compositions comprising said compounds, and methods for using said compounds for the treatment of diseases. These compounds are covalent small molecule inhibitors,

COMPOUNDS AND USES THEREOF

The present invention relates to methods and compositions for the treatment of BAF-related disorders such as cancers and viral infections.

Pyrazole compound, medicine composition containing pyrazole compound and application

The invention relates to a pyrazole compound, a medicine composition containing the pyrazole compound and application. The pyrazole compound is of a structure shown in a formula (I) as shown in the description. The compound can be used for inhibiting IRAK

HETEROARYLDIHYDROPYRIMIDINE DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS

Provided herein are compounds useful for the treatment of HBV infection in a subject in need thereof, pharmaceutical compositions thereof, and methods of inhibiting, suppressing, or preventing HBV infection in the subject.

Preparation method of four-membered azacyclo intermediate

The invention relates to a preparation method of a four-membered azacyclo intermediate. The preparation method comprises following steps: a compound represented by formula 1 is subjected to reaction at alkaline conditions so as to generate a compound repr

BENZOSULFONYL COMPOUNDS

Provided herein are compounds and pharmaceutical compositions comprising said compounds that are useful for treating cancers. Specific cancers include those that are mediated by YAP/TAZ or those that are modulated by the interaction between YAP/TAZ and TEAD.

SUBSTITUTED 5-CYANOINDOLE COMPOUNDS AND USES THEREOF

A compound of Formula (I), or a pharmaceutically acceptable salt thereof, is provided that has been shown to be useful for the treatment of lysine (K)-specific demethylase 1A (LSD1) - mediated diseases or disorders, Formula (I), wherein R1, R2, R3, R4, and R5 are as defined herein.

Reaction Rates of Various N-Acylenamines in the Inverse-Electron-Demand Diels–Alder Reaction

In light of the bioorthogonal inverse-electron-demand Diels–Alder strategy, an extended investigation into the effects of ring strain and electron inductive effects on the reactivity of the N-acylenamine core towards tetrazine has been carried out. Through a comparative study between N-acylazetines, N-vinylcarbamates and an N-vinylamide it was shown that ring strain has a more significant effect on reaction rate than electron donation. A significantly improved synthetic route is reported for the preparation of an N-acylazetine biorthogonal tag we have invented previously.